Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
National Institute on Aging (NIA) |
---|---|
Information provided by: | National Institute on Aging (NIA) |
ClinicalTrials.gov Identifier: | NCT00608062 |
The purpose of this study is to find out why women's arteries stiffen as they go through menopause, and how this is affected by estrogen loss. We believe that arteries stiffen with the loss of estrogen because of "oxidative stress," the production of molecules that can damage cells and tissues in the body, and because the arteries lose their ability to expand, or dilate.
Condition | Intervention |
---|---|
Arterial Stiffening Aging Menopause |
Drug: GnRHant - Ganirelix acetate Drug: Transdermal estradiol patch Drug: Transdermal placebo patch |
Study Type: | Interventional |
Study Design: | Basic Science, Randomized, Double Blind (Subject, Investigator), Parallel Assignment |
Official Title: | Biological Mechanisms of Arterial Stiffening With Age and Estrogen Deficiency |
Estimated Enrollment: | 124 |
Study Start Date: | March 2007 |
Estimated Study Completion Date: | March 2011 |
Estimated Primary Completion Date: | March 2011 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
Pre1: Experimental
Premenopausal - GnRHant plus estradiol
|
Drug: GnRHant - Ganirelix acetate
1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7
Drug: Transdermal estradiol patch
0.075mg/d starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)
|
Pre2: Placebo Comparator
Premenopausal - GnRHant plus placebo
|
Drug: GnRHant - Ganirelix acetate
1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7
Drug: Transdermal placebo patch
Starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)
|
Peri1: Experimental
Perimenopausal (early) - GnRHant plus estradiol
|
Drug: GnRHant - Ganirelix acetate
1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7
Drug: Transdermal estradiol patch
0.075mg/d starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)
|
Peri2: Placebo Comparator
Perimenopausal (early) - GnRHant plus placebo
|
Drug: GnRHant - Ganirelix acetate
1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7
Drug: Transdermal placebo patch
Starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)
|
Peri3: Experimental
Perimenopausal (late) - GnRHant plus estradiol
|
Drug: GnRHant - Ganirelix acetate
1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7
Drug: Transdermal estradiol patch
0.075mg/d starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)
|
Peri4: Placebo Comparator
Perimenopausal (late) - GnRHant plus placebo
|
Drug: GnRHant - Ganirelix acetate
1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7
Drug: Transdermal placebo patch
Starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)
|
Post1: Experimental
Postmenopausal - GnRHant plus estradiol
|
Drug: GnRHant - Ganirelix acetate
1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7
Drug: Transdermal estradiol patch
0.075mg/d starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)
|
Post2: Placebo Comparator
Postmenopausal - GnRHant plus placebo
|
Drug: GnRHant - Ganirelix acetate
1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7
Drug: Transdermal placebo patch
Starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)
|
As women get older and go through menopause, estradiol levels decrease. Also with aging, the arteries that are located around the heart get stiffer. Over time this increase in arterial stiffness can lead to a number of health problems such as high blood pressure and heart disease. In this study we want to find out if a short-term drop in estrogen levels in premenopausal and perimenopausal women can cause arteries to become stiffer, and why this happens. Additionally, in postmenopausal women, we want to find out if a short-term increase in estrogen levels causes their arteries to become more flexible (less stiff).
Arterial health (i.e., stiffness) will be examined in premenopausal, perimenopausal and postmenopausal women before and after they are given a drug called Ganirelix™ (for 7 days), which will markedly lower their reproductive hormones. After the first 4 days of taking Ganirelix™, the women will be randomly placed into 1 of 2 treatment groups to take either estrogen (0.075 mg/d skin patch) replacement or placebo for the rest of the Ganirelix treatment. This is to increase estrogen levels back to the normal level. After having the patch on for 4 days, arterial health will be examined again.
Ages Eligible for Study: | 21 Years to 70 Years |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Healthy women of all races and ethnic backgrounds in one of the following groups:
Exclusion Criteria:
Contact: Kalen Abbott | 720-848-6418 | Kalen.Abbott@uchcs.edu |
Contact: Nicole Hirsch | 720-848-6396 | Nicole.Hirsch@uchsc.edu |
United States, Colorado | |
University of Colorado Denver General Clinical Research Center and Exercise Research Laboratory | Recruiting |
Aurora, Colorado, United States, 80045 | |
Contact: Tim Lockie, MS, MBA 720-848-6660 Tim.Lockie@uchsc.edu | |
Principal Investigator: Kerrie L Moreau, PhD | |
Sub-Investigator: Wendy M. Kohrt, PhD |
Principal Investigator: | Kerrie L Moreau, PhD | University of Colorado Denver |
Responsible Party: | University of Colorado Denver ( Kerrie L. Moreau, PhD, Assistant Research Professor ) |
Study ID Numbers: | AG0094, R01AG027678 |
Study First Received: | January 31, 2008 |
Last Updated: | January 31, 2008 |
ClinicalTrials.gov Identifier: | NCT00608062 |
Health Authority: | United States: Federal Government |
endothelial function women female estrogen deficiency |
sex hormones adiposity oxidative stress antioxidants |
Atherosclerosis Obesity Ganirelix Estradiol 3-benzoate Estradiol valerate |
Stress Estradiol 17 beta-cypionate Polyestradiol phosphate Estradiol Menopause |
Hormone Antagonists Physiological Effects of Drugs Hormones, Hormone Substitutes, and Hormone Antagonists Pharmacologic Actions |